NCT07594691

Brief Summary

This is a prospective quality improvement study. The INEX RT P study will prospectively evaluate INEX RT R that optimizes radiation dose delivery to the target while minimizing dose to critical organs at risk (OAR) by treating patients with different phases of breath hold (inhale and exhale) during the same course of SBRT. 15 patients with abdominal cancer whom are expected to achieve a dosimetric advantage from this technique due to OAR proximity to target will be treated using INEX RT. We hypothesize that we can increase the dose to the RT target by at least 10% while simultaneously decreasing or maintaining dose to adjacent critical OARs when using a combination of breath hold positions to purposefully vary the position of OARs during different fractions of the same treatment course when compared to RT treatments planned on a single breath hold phase alone (present standard of care).

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
21mo left

Started May 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 13, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 19, 2026

Completed
1 day until next milestone

Study Start

First participant enrolled

May 20, 2026

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2027

Expected
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2028

Last Updated

May 19, 2026

Status Verified

May 1, 2026

Enrollment Period

1 year

First QC Date

May 13, 2026

Last Update Submit

May 13, 2026

Conditions

Keywords

INEX RTSBRTBreathBreath Hold Immobilization

Outcome Measures

Primary Outcomes (1)

  • Total dose to radiation targets and OARs

    Total dose to radiation targets and OARs on standard workflow (FB ITV or exhale/inhale single breath hold phase only) compared to INEX RT. Unit: Gy

    12 Months

Secondary Outcomes (1)

  • Positional change between a deep inhale and deep exhale breath hold

    12 Months

Study Arms (1)

Imaging

EXPERIMENTAL
Diagnostic Test: Simulation and treatment imaging

Interventions

Obtain inhale and exhale breath hold images planned to split radiation delivery between inhale and exhale breath hold phases. For radiotherapy courses with an odd number of fractions, the phase of breath hold with higher reproducibility or anatomic advantage will be used for the additional fraction of radiotherapy. If during the treatment planning the investigators determine that the patients will benefit from the multiple breath holds technique, the patients will be treated using the composite breath hold plan. Additional one or two cone beam CTs will be obtained on treatment days for all patients using the inhale and exhale breath hold technique.

Imaging

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18
  • Any patient undergoing radiation therapy for a cancer lesion in the abdomen in close proximity to OARs that is hypothesized to have differential displacement on inhale and exhale breath hold CT scans of the OAR relative to the tumor.
  • Patients need at least 3 fractions of RT
  • Critical OARs are within 2 cm of luminal GI structures, chest wall, or previous radiation fields
  • Able to receive and understand verbal and written information regarding study and able to give written informed consent

You may not qualify if:

  • Inability to perform inhale or exhale breath holds during standard workflow CT simulation evaluation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Princess Margaret Cancer Centre Toronto, Ontario

Toronto, Ontario, M5G 2M9, Canada

Location

Central Study Contacts

Laura Dawson, MD FRCPSC FASTRO FCAHS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 13, 2026

First Posted

May 19, 2026

Study Start

May 20, 2026

Primary Completion (Estimated)

May 30, 2027

Study Completion (Estimated)

January 30, 2028

Last Updated

May 19, 2026

Record last verified: 2026-05

Locations